HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Camus, Ph. Articles by Ask, K. Search for Related Content PubMed PubMed Citation Articles by Camus, Ph. Articles by Ask, K.

Drug-induced infiltrative lung disease

Service de Pneumologie et de Réanimation Respiratoire, Centre Hospitalier Universitaire de Dijon, et Unité de Pharmacologie Toxicologie Pulmonaire, Université de Bourgogne, Dijon, France

CORRESPONDENCE: Ph. Camus, Service de Pneumologie et de Réanimation Respiratoire, CHU de Dijon, Dijon, France. Fax: 33 380293251

Keywords: drug-induced lung disease, drugs, lung toxicity, patients, registry, web technology

Received: March 8, 2001
An increasing number of drugs are recognized to induce distinctive patterns of infiltrative lung disease (ILD), ranging from benign infiltrates to life-threatening adult respiratory distress syndromes. In addition to drugs, biomolecules such as proteins and cytokines, and medicinal plants are also capable of inducing respiratory disease, some being severe and/or irreversible.

For several reasons it is difficult to estimate the exact frequency of drug-induced infiltrative lung disease (DI-ILD). The risk for DI-ILD and the clinical patterns vary depending on a variety of host and drug factors.

Although establishing the diagnosis is often difficult, systematic evaluation of the possible role of almost any kind of drugs in ILD is warranted, as stopping a drug may favourably influence prognosis. However, prognosis depends on the drug and the type of DI-ILD. Corticosteroids may suppress the inflammatory reaction, but for many drugs, proof of the effect of corticosteroids is lacking.

Advances in prevention and prediction are needed. A user-friendly database of respiratory adverse drug reactions was made available on the web, to provide quick information in this area.

This article has been cited by other articles:

				C. Terzano and A. Petroianni Clarithromycin and pulmonary infiltration with eosinophilia BMJ, June 19, 2003; 326(7403): 1377 - 1378. [Full Text] [PDF]